Get access

Mutasynthesis of Fluorosalinosporamide, a Potent and Reversible Inhibitor of the Proteasome

Authors

  • Alessandra S. Eustáquio Dr.,

    1. Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0204, USA, Fax: (+1) 858-534-1305
    Search for more papers by this author
  • Bradley S. Moore Prof. Dr.

    1. Scripps Institution of Oceanography and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California at San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0204, USA, Fax: (+1) 858-534-1305
    Search for more papers by this author

  • This work was supported by a grant from the National Institutes of Health (grant no.: CA127622 to B.S.M.). A.S.E. is a Tularik postdoctoral fellow of the Life Sciences Research Foundation. We thank M. Onega and D. O'Hagan (University of St. Andrews, UK) for kindly providing 5′-fluoro-5′-deoxyadenosine and 5-fluoro-5-deoxyribose and J. Haerle, S. Kelly, and J. Kalaitzis (University of California at San Diego, USA) for technical help with fermentation, cytotoxicity assays, and NMR analysis, respectively.

Abstract

original image

Fluorsubstituenten können Wirkstoffen vorteilhafte Eigenschaften verleihen. Mithilfe von Gen-Engineering und vorstufengelenkter Biosynthese wurde Fluorsalinosporamid (siehe Schema) durch Fermentierung erhalten. Die biologische Aktivität dieser Verbindung als Proteasom-Inhibitor wurde mit derjenigen des Chlor-Analogons Salinosporamid A, eines marinen Naturstoffs, der als Leitstruktur für Krebstherapeutika dient, verglichen.

Get access to the full text of this article

Ancillary